- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Torrent Pharma, Eli Lilly ink pact to boost Baricitinib production in India
Ahmedabad: Following in the footsteps of Sun Pharma, Cipla, and Lupin in signing a voluntary licencing agreement with Eli Lilly to accelerate the production of Baricitinib for the treatment of COVID-19 patients in India, now Torrent Pharmaceuticals has signed a royalty free, non-exclusive voluntary licencing agreement with Eli Lilly to boost the production of Baricitinib.Under the...
Ahmedabad: Following in the footsteps of Sun Pharma, Cipla, and Lupin in signing a voluntary licencing agreement with Eli Lilly to accelerate the production of Baricitinib for the treatment of COVID-19 patients in India, now Torrent Pharmaceuticals has signed a royalty free, non-exclusive voluntary licencing agreement with Eli Lilly to boost the production of Baricitinib.
Under the agreement, Lilly has provided the license to manufacture and distribute baricitinib to Torrent for India along with Lilly's other license partners.
Read also: Eli Lilly ink licensing pact with Sun Pharma, Cipla, Lupin to expedite COVID drug Baricitinib
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751